Browsing Category
Featured Articles
Lonza to Acquire Five US Manufacturing Sites from Merck KGaA
Lonza, a Switzerland-based contract development and manufacturing organization (CDMO), has signed an agreement to acquire five manufacturing sites from Germany's Merck KGaA in a deal…
Read More...
Read More...
FDA Accepts uniQure’s Gene Therapy Application for Huntington’s Disease
uniQure N.V. has received an important regulatory milestone in its effort to develop a gene therapy for Huntington’s disease after the US Food and Drug Administration (FDA) accepted its…
Read More...
Read More...
Glenmark Opens Major US Pharmaceutical Distribution Center in Pennsylvania
Glenmark Pharmaceuticals has inaugurated a new distribution center in Allentown, Pennsylvania, marking an important expansion of its operations and pharmaceutical supply chain in the…
Read More...
Read More...
Lilly’s Retatrutide Shows Greater A1C Reduction in Type 2 Diabetes Trial
Eli Lilly’s experimental obesity and diabetes drug retatrutide has delivered stronger blood sugar control and more than twice the weight loss compared with Novo Nordisk’s Ozempic in a…
Read More...
Read More...
Pfizer’s Talzenna Combination Wins FDA Approval for Earlier Prostate Cancer
Pfizer has received US Food and Drug Administration (FDA) approval to expand the use of Talzenna (talazoparib) in combination with Xtandi (enzalutamide) for men with a specific type of…
Read More...
Read More...
AstraZeneca Wins FDA Approval for Ultomiris in IgA Nephropathy
AstraZeneca has received accelerated approval from the US Food and Drug Administration (FDA) for Ultomiris (ravulizumab) to reduce protein levels in the urine of adults with primary…
Read More...
Read More...
GSK Wins FDA Approval for Hibsago to Treat Chronic Hepatitis B
GSK has received approval from the US Food and Drug Administration (FDA) for Hibsago (bepirovirsen), a new treatment for certain adults living with chronic hepatitis B. The approval…
Read More...
Read More...
EU Approves Keytruda and Padcev for Muscle-Invasive Bladder Cancer
The European Commission has approved Merck’s Keytruda (pembrolizumab) in combination with Padcev (enfortumab vedotin-ejfv) as a perioperative treatment for adults with resectable…
Read More...
Read More...
Merck KGaA to Acquire Silence Therapeutics for $1.3 Billion
Merck KGaA, Darmstadt, Germany, has agreed to acquire Silence Therapeutics, a UK-based biotechnology company, in an all-cash deal valued at approximately $1.3 billion. The acquisition…
Read More...
Read More...
Lilly’s Omvoh Meets Phase 3 Goal in Pediatric Ulcerative Colitis
Eli Lilly and Company has announced positive Phase 3 clinical trial results for Omvoh (mirikizumab-mrkz) in children and adolescents with moderately to severely active ulcerative…
Read More...
Read More...
Roche Wins FDA Approval for Enspryng in Thyroid Eye Disease
Roche has received approval from the U.S. Food and Drug Administration (FDA) for Enspryng (satralizumab) to treat adults with thyroid eye disease (TED). The approval introduces the…
Read More...
Read More...
Vir Biotechnology and Gilead Partner on Solid Tumor T-Cell Engagers
Vir Biotechnology has signed a collaboration and licensing agreement with Gilead Sciences to discover and develop three novel T-cell engager (TCE) candidates targeting solid tumors. The…
Read More...
Read More...
Charles River Partners with Magellan to Advance Stem Cell Therapy
Charles River Laboratories has partnered with Australian biotechnology company Magellan Stem Cells to support the development and clinical advancement of its stem cell therapies,…
Read More...
Read More...
Teva Wins FDA Approval for Once-Monthly Schizophrenia Injection
Teva Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for WELTRUZA (olanzapine), a once-monthly injectable treatment for adults with schizophrenia.…
Read More...
Read More...
Cognizant Extends Gilead Partnership to Expand AI-Enabled DevOps
Cognizant has extended its partnership with Gilead Sciences for five years to support the biopharmaceutical company’s technology programs, with a focus on DevOps and the responsible use…
Read More...
Read More...
AstraZeneca Opens $1B R&D Centre in Cambridge
AstraZeneca has opened a new global research and development (R&D) centre in Kendall Square, Cambridge, Massachusetts, as part of a more than $1 billion investment in the state.…
Read More...
Read More...
Sanofi, Regeneron Expand Antibody Collaboration With $8B Deal
Sanofi and Regeneron Pharmaceuticals are expanding their long-running antibody collaboration to develop four next-generation, long-acting treatments for immune-mediated diseases.
The…
Read More...
Read More...
Abogen, Novartis Sign $7.2B RNA Therapeutics Deal
Abogen Biosciences has entered into a licensing and option agreement with Novartis to develop RNA-encoded therapies, including a potential new treatment approach for autoimmune…
Read More...
Read More...
FDA Expands Camzyos Approval to Children With oHCM
The U.S. Food and Drug Administration (FDA) has expanded the approval of Bristol Myers Squibb’s Camzyos (mavacamten) to include pediatric patients with symptomatic obstructive…
Read More...
Read More...
AbbVie’s Juvmo Wins FDA Approval for Parkinson’s Disease
AbbVie has received U.S. Food and Drug Administration (FDA) approval for JUVMO (tavapadon), a once-daily oral treatment for adults with Parkinson’s disease. The approval makes JUVMO the…
Read More...
Read More...
